News – Page 145 – Selby Spine

ATLANTA, Sept. 28, 2017 /PRNewswire/ — Resurgens Spine Center, the largest spine specialty center in the state, recently announced the addition of three fellowship-trained surgeons. With the addition of Dr. Uzondu Agochukwu, Dr. Christopher Blanchard, and Dr. Vamsi Kancherla, Resurgens Spine Center now offers nearly 30 spine physicians to serve our local communities.

“These three highly-trained spine surgeons make Resurgens Spine Center even more equipped to serve all patients experiencing neck and back pain throughout metro Atlanta,” said Dr. Thomas Dopson, Co-Medical Director of Resurgens Spine Center. “Each of them have been trained in the latest nonsurgical and surgical techniques, including Minimally Invasive Spine Surgery and Total Disc Replacement.”

The Resurgens Spine Center staff uses clinical protocols and the latest technology for a range of specialties. These include: Physiatry (Physical Medicine and Rehabilitation); Spine Surgery; Minimally Invasive Spine Surgery; Spine Therapy; Diagnostic Imaging; Interventional Injections; Electrodiagnostics; and treatment of Worker’s Compensation Injuries.

“Our goal is to help people overcome their injuries and get back to doing what they love,” Dr. Dopson explained. “We are excited for these doctors to join us in achieving that mission.”

Resurgens Spine Center is pleased to introduce the following spine specialists to the communities they serve:

Dr. Uzondu Agochukwu

Education: He received his medical degree from Indiana University and completed his residency at Madigan Army Medical Center in Tacoma, Wash. He completed his Spine Fellowship at Augusta University Health in Augusta, Ga.and is board certified.
Locations: 105 Regency Park Drive, McDonough. 770-506-4119.
665 South 8th St., Griffin. 770-227-7050.
6635 Lake Drive, Morrow. 770-968-1323.

Dr. Christopher Blanchard

Education: After receiving his medical degree from Philadelphia College of Osteopathic Medicine in Suwanee, Georgia, he completed his residency at Doctors Hospital in Columbus, Ohio. He completed his Spine Fellowship at Duke University Medical Center in Durham, N.C.
Location: 4150 Deputy Bill Cantrell Memorial Road, Suite 300, Cumming. 770-886-8111.

Dr. Vamsi Kancherla

Education: He received his medical degree from the Perelman School of Medicine at the University of Pennsylvaniain Philadelphia, Penn. and completed his residency at St. Luke’s University Hospital in Bethlehem, Penn. He completed his Spine Fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio.
Location: 5671 Peachtree Dunwoody Road, Suite 900, Atlanta, Ga. 404-847-9999.

Resurgens Spine Center is a member of Resurgens Orthopaedics, one of the nation’s largest orthopaedic practices. Resurgens Orthopaedics has 22 offices throughout metro Atlanta, serving the residents of Georgia, the Southeast and beyond. Each location offers comprehensive operative and non-operative musculoskeletal care, from injury diagnosis and treatment to rehabilitation and imaging services. With more than 100 physicians, Resurgens Orthopaedics provides specialized expertise and broad experience in the areas of sports medicine, joint replacement, neck and back surgery, foot and ankle surgery, shoulder and elbow surgery, non-operative spine care, hand surgery, arthroscopic surgery, epidural steroid injection, general orthopaedics, and trauma care.

Resurgens Spine Center – Reach for MORE.

Learn more at resurgens.com/spine.

Patient and physician interviews available upon request.

Contact: Jon Waterhouse | Lenz, Inc.
404-373-2021
jwaterhouse@lenzmarketing.com

SOURCE Resurgens Spine Center

September 28, 2017

SAFE ORTHOPAEDICS (FR0012452746 – SAFOR) (Paris:SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, today announces its results for the first half of 2017.

Safe Orthopaedics’ half-year report will be available in the Investors > Documentation > Regulated Information section of the Company’s website (www.SafeOrtho.com) from September 29, 2017.

€ thousands – IFRS	30/06/2017	30/06/2016
Revenues – France	803	599
Revenues – Rest of the world	841	605
Adjusted total revenues¹	1,644	1,204
Revenues from discontinued activities	0	99
Total revenues	1,644	1,303
Purchases used and change in inventories	(839)	(981)
External costs	(1,221)	(1,362)
Personnel costs	(1,659)	(2,010)
Other operating expenses	(406)	(351)
Operating income/(loss) before non-recurring items	(2,481)	(3,402)
Other operational income and expenses	(49)	(10)
Operating income/(loss)	(2,530)	(3,412)
Financial income/(loss)	(716)	(158)
Net income/(loss)	(3,245)	(3,559)

In the first half of 2017, adjusted revenues¹ saw growth (+37% to €1,644 thousand), driven by an improvement in all zones, France and the Rest of the World, as well as the opening of the first client accounts in Germany. The strengthening of the French sales team has enabled the Company to double its domestic growth. Combined with the regular growth recorded by its longstanding distributors, the commercial launch in South America has helped accelerate export sales.

Subsequently, the operating loss before non-recurring items improved by €900 thousand over the period (-€2.5 million, versus -€3.4 million in the first half of 2016). Once a financial loss of €716 thousand associated with negative currency effects due to the balance intra-group (US subsidiary), is taken into account, there was a net loss of -€3.2 million in H1 2017, compared with -€3.6 million a year earlier.

At June 30, 2017, Safe Orthopaedics had a cash position of €995 thousand, versus €4.25 million at end-June 2016. However, this figure does not incorporate the €5.8 million fundraising operation carried out in early July in order to finance the hiring of new reps in Europe, accelerate its disposable conversion strategy by market segment and extend its international distribution network.

“Over the first half of 2017, Safe Orthopaedics continued its transformation from an R&D-centric company to one focused first and foremost on marketing its single-use innovative technologies for emergency spinal surgeries and increasing its sales”, said Pierre Dumouchel, CEO and co-founder of Safe Orthopaedics. “Given this significant improvement in our results and the success of early July’s capital increase, we remain resolutely confident and intent on continuing Safe Orthopaedics’ commercial development and recruiting talented new sales and marketing staff to continue our growth quarter by quarter”.

Next financial press release: revenues for the 3^rd quarter of 2017, on Monday October 9 (after market)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpine^TM kits are CE-marked and FDA approved. The company is based at Eragny-sur-Oise (Val d’Oise department), and has 30 employees.

For more information, visit: www.SafeOrtho.com

¹Revenues adjusted for activities discontinued in the United States since March 1, 2016

Contacts

Safe Orthopaedics
Pierre Dumouchel, Tél.: +33 (0)1 34 21 50 00
CEO
investors@safeorthopaedics.com
or
NewCap
Julien Perez / Valentine Brouchot
Investor Relations
Nicolas Merigeau
Media Relations
Tél.: +33 (0)1 44 71 94 94
SafeOrtho@newcap.eu

OR AKIVA, Israel, September 28, 2017 /PRNewswire/ —

Expanding Orthopedics Inc. (EOI), a privately-held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, today announced FDA 510(k) clearance for the FLXfit™15, enhancing the already successful FLXfit™ 3D Expandable Cage System. The FLXfit™15 will expand the surgeon’s flexibility and capability by offering a family of products in different length options with infinitely adjustable expansion and lordosis correction of upto 4mm and 15⁰.

Dale Binke, EOI’s VP of US Sales, notes that, “One of the major trends in fusion surgeries is progression towards MIS style procedures, inpatient or outpatient.” However, Dale explains, “There is an inherent challenge in inserting a large interbody cage that restores lumbar lordosis while controlling sagittal and coronal alignment.” He adds, “The FLXfit expandable cage is already providing the ultimate expandable TLIF solution, combining the best-in-class footprint that can be delivered through a MIS window and a unique expansion mechanism that restores lordosis.” Dale summarizes, “With the FLXfit15™, EOI’s engineering team has pushed the envelope a step further by combining an articulating cage with optimal footprint which can be easily delivered and expanded in a controlled manner up to 4mm and 15⁰ of lordotic restoration.”

Expandable cages are gaining market momentum and play a key role in successful fusion procedures. Ofer Bokobza, CEO of Expanding Orthopedics, comments, “The FLXfit™ System has already trail blazed the way for anatomical fit, expandable cages by providing great clinical promise so far.” Ofer says, “The FLXfit15™ will further enhance the anatomical fit with its 15⁰ lordosis and the shorter footprint version (32mm) will offer great flexibility in treating patients with smaller anatomies.” He concludes, “We are thrilled with the release of the FLXfit™15 in the US and certain that the enhanced versatility of the new FLXfit™ family will help gain a greater share in the fusion surgery market, both in MIS and open approaches.”

About Expanding Orthopedics Inc.

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients’ outcome. The Company is spearheaded by a seasoned management team, and is advised by a prominent team of spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaim,
VP Marketing and Sales
E-mail: david@xortho.com
Phone: (347)-3219683

WALNUT CREEK, Calif., Sept. 27, 2017 /PRNewswire/ — Providence Medical Technology, an innovator in cervical spine fusion, today announced FDA 510K clearance for its ALLY™ Posterior Fixation System. The system is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for acute and chronic instabilities of the cervical spine (C1 to C7) and is compatible with the company’s flagship DTRAX® Spinal System.

DTRAX Spinal System is a set of sterile packaged, single-use instruments designed to perform posterior cervical fusion and has been used in over 7,000 cases worldwide. Posterior cervical fusion is indicated for patients with symptomatic nerve root involvement and/or mechanical instability. Spinal implants are typically used as an adjunct to posterior cervical fusion cases, and the newly cleared ALLY Posterior Fixation System is the latest addition to the family of spinal fusion implants offered by Providence. Providence also offers CAVUX® Cervical Cages, ALLY Bone Screws, and ALLY Facet Screws as options for spinal instrumentation during cervical fusion procedures.

“We are encouraged by the continued adoption of our posterior cervical fusion technology. Surgeons are increasingly considering posterior cervical fusion with intervertebral cages and supplemental screw fixation when treating patients with cervical spine disorders,” said Providence CEO, Jeff Smith. “The regulatory clearance of ALLY Posterior Fixation System is an important milestone and reflects our commitment to continued innovation and expansion of our differentiated product offering.”

Providence recently announced multiple independent clinical studies supporting the safety, efficacy, and cost-efficiency of its posterior cervical fusion technology. The company will be exhibiting at the annual meeting of the North American Spine Society (NASS) in Orlando, Florida, on October 25-28, booth #1140.

About Providence Medical Technology, Inc.
Providence Medical Technology, Inc. is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to posterior cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY™ line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance. For more information, visit www.providencemt.com

SOURCE Providence Medical Technology

MALDEN, MASS. (PRWEB) SEPTEMBER 27, 2017

AxioMed clinical experience across continents continues to point to the benefits of the AxioMed disc replacement, as Professor Dr. Kingsley R. Chin shares his clinical assessment, stating, “I was pleased with the motion seen between the spinous processes and facets immediately after implanting the AxioMed viscoelastic cervical disc during a recent case in Kingston, Jamaica. I noted that the disc needs some time to warm to body temperature to see more compression of the disc. In this case we inspected the motion immediately after implantation while the wound was still open.”

President of AxioMed Jake Lubinski added, “Dr. Chin’s experience is being echoed by surgeons, many implanting the disc for the first time, who can’t believe how simple and natural the sizing and placement of the disc is.”

Dr. Chin emphasized how easy the surgery is, pointing out, “Surgeons who have implanted the cervical or lumbar AxioMed Freedom discs all share their amazement at how simple the discs are to implant and how well the patients do. I expect this experience will result in a revolutionary change in spinal care from fusions to viscoelastic discs.”

Dr. Kingsley R. Chin is a Bohlman trained and board certified orthopedic spine surgeon who practices at the LESS Institute in Florida.

To view the latest cervical and lumbar AxioMed cases done in the past two weeks, visit AxioMed on YouTube.

About AxioMed
Founded in 2001, AxioMed began its journey of exhaustively proving the Freedom® disc through clinical studies in the U.S. and Europe, research, development and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom disc technology.

MINNEAPOLIS, Sept. 27, 2017 /PRNewswire/ — Conventus Orthopaedics, a medical device company revolutionizing fracture repair surgery, today announced that Richard Mott has been appointed to its Board of Directors, effective immediately.

Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm, where he provides strategic counsel to operating teams for several privately held medical technology and biotech entities in various stages of development. He is the current Chairman of Silk Road Medical, Relievant MedSystems and 480 Biomedical. Previously, Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc in late 2007. Prior to Kyphon, Mr. Mott held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company.

“We are pleased to welcome Rich to our Board and look forward to benefiting from his extensive track record of success and leadership in the orthopaedic industry,” said Matthew Jewett, President and Chief Executive Officer of Conventus. “His experience in building and scaling high potential medical device platforms will be invaluable as we continue to introduce additional innovative Cage technology solutions and build a solid foundation for future commercial growth.”

“I am excited to join an organization dedicated to revolutionizing fracture repair surgery and improving outcomes for patients,” said Richard Mott. “It is an especially exciting time to be a part of Conventus as the company prepares to launch an enhanced proximal humerus (PH) system and as compelling data on 125 proximal humerus patients will be presented at the Orthopaedic Trauma Association (OTA) conference in Vancouver next month.”

About Conventus Orthopaedics, Inc.
Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a 3-dimensional platform technology with less invasive solutions to a broad range of challenging periarticular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions to fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients’ return to normal activities.

SOURCE Conventus Orthopaedics, Inc.

PUNE, India, September 27, 2017 /PRNewswire/ —

According to a new market research report “Orthobiologics Market by Product (Viscosupplementation, Synthetic Orthobiologics, DBM, BMP, PRP, BMAC, Allograft), Application (Fracture Recovery, Osteoarthritis, Spinal Fusion, Soft Tissue), End User (Hospitals, ASCs, Academia) – Global Forecast to 2022“, published by MarketsandMarkets™, the market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period.

Browse 60 Market Data Tables and 38 Figures spread through 159 Pages and in-depth TOC on “Orthobiologics Market“

http://www.marketsandmarkets.com/Market-Reports/orthobiologics-market-162747970.html
Early buyers will receive 10% customization on this report

The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the Orthobiologics Market in North America, Europe, Asia Pacific, and the Rest of the World (RoW). Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the Orthobiologics Market. However, high cost pertaining to orthobiologics based treatment is the major factor restraining the market growth to a certain extent.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=162747970

Based on product, the viscosupplementation products segment is estimated account for the largest segment of the market in 2017

On the basis of product, the Orthobiologics Market is segmented into allografts, synthetic orthobiologics, plasma-rich protein (PRP), bone marrow aspirate concentrate (BMAC), demineralized bone matrices (DBM), bone morphogenic protein (BMP), and viscosupplementation products. The viscosupplementation products segment is expected to account for largest share of the Orthobiologics Market in 2017. The large share of this segment can be attributed to the increasing incidence of osteoarthritis of the knee and hip joints among the baby boomer population and lower cost of viscosupplementations.

Based on application, the osteoarthritis and degenerative arthritis segment expected to account for the largest share of the market in 2017

Based on application, the Orthobiologics Market is segmented into fracture recovery, osteoarthritis & degenerative arthritis, spinal fusion, soft tissue injuries, and maxillofacial & dental applications. The osteoarthritis and degenerative arthritis segment is estimated to command the largest share of the global Orthobiologics Market in 2017. The large share of this segment is mainly due to factors such as the significant rise in target patient population across major markets, rising public awareness related to clinical side effects associated with oral medications for pain management, clinical advancements in OA management methodologies, robust healthcare infrastructure & facilities for specific joint replacement surgeries across major markets, and growing clinical evidence validating the efficacy of biologics in OA treatment.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=162747970

In 2017, North America is expected to account for the largest share of the Orthobiologics Market

Geographically, the Orthobiologics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global Orthobiologics Market in 2017. The growth of this region is attributed to rising incidence of orthopedic and spinal disorders; increasing geriatric population coupled with obesity; growing population exposure to key risk factors; rising number of spinal fusion surgeries and rising patient preference for minimally invasive orthopedic therapies over invasive grafting procedures; and growing physician and patient awareness about the newly introduced treatment procedures and technologies.

The major players in the market are DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, Bioventus, NuVasive, SeaSpine, Arthrex, and Xtant Medical.

Browse Related Reports:

Bone Growth Stimulator Market by Product (Device, Bone Morphogenetic Protein, PRP), Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial), End User (Hospitals, Home Care, Academia, CROs) – Global Forecasts to 2022

http://www.marketsandmarkets.com/Market-Reports/bone-growth-stimulator-market-82341383.html

Spine Biologics Market by Product Type (Bone Graft, Bone Graft Substitute, Platelet Rich Plasma, BMAC), Surgery Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography-Global Forecast to 2020

http://www.marketsandmarkets.com/Market-Reports/spine-biologics-market-67680943.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit Our Blog@ http://mnmblog.org/market-research/healthcare/medical-devices

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets

rea-medicrea-5a4276cf1b952a23a2381b1b66a95324546377b474c62e264272afb9a3c02711.jpg

September 27, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, will announce its 2017 Half-Year Results on Monday, 2 October, after market.

On the following day, Tuesday, 3 October, Medicrea will participate in a meeting organized by SFAF (French Society of Financial Analysts) to present the Company’s strategy and results.

The upcoming dates announced on the original schedule remain otherwise unchanged:

	• 2017 Third Quarter sales	October 12, 2017*

	• 2017 Annual sales	January 11, 2018*

*Subject to modification. After market.

Next publication: 2017 Half-Year Results on 2 October, after market.

About Medicrea (www.Medicrea.com)

Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 100,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

For further information, please visit: Medicrea.com.

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED

Contacts

Medicrea
Denys Sournac
Founder, Chairman and CEO
dsournac@Medicrea.com
or
Fabrice Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@Medicrea.com

AUSTIN, TX September 26, 2017 – Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced the commercial availability of the revised VariLift®-C System throughout the U.S.

VariLift-C is now available in three heights, 8mm 9mm and 10mm, allowing surgeons to implant an optimally sized device in a broader patient population. Instrumentation has been modified to reduce size and to improve usability and ergonomics.

“The new features of the VariLift-C system enhances ease of use, and reduces overall exposure and instrumentation footprint. My patients have experienced excellent symptom relief and very low complication rates. In nearly all cases, VariLift-C procedures are done as outpatient surgeries, with patients returning home same day.” said Dr. Benjamin Gelber, M.D., Chairman, Division of Neurosurgery, Bryan LGH Medical Center in Lincoln, NB and Clinical Associate Professor, Department of Neurosurgery, University of Nebraska College of Medicine. He further added “Another benefit is no separate bone graft harvest or extenders are necessary for the VariLift-C. procedure. These enhanced features contribute to a very high success rate for my patients.”

VariLift-C is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level. VariLift-C is used to facilitate intervertebral body fusion in the cervical spine and is placed in a unilateral or a bilateral fashion via an anterior approach at the C3 to C7 disc levels using autograft bone.

VariLift-C may be used with or without supplemental fixation.

Wenzel Spine’s Cervical VariLift® Stand-Alone Expandable Interbody Fusion System and the redesigned instruments are now commercially available in the U.S.

About Wenzel Spine, Inc.

Wenzel Spine, Inc. is a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders. Headquartered in Austin, TX, Wenzel Spine is focused on delivering surgical solutions that improve the overall quality of spine care by simplifying procedures and reducing recovery time. Wenzel Spine seeks to improve patient quality of life by designing and producing devices of the highest quality to support our surgeon clients in the care and treatment of their patients. For more information about the company and our products, visit www.wenzelspine.com.

Follow Wenzel Spine on LinkedIn: https://www.linkedin.com/company/wenzel-spine
Follow Wenzel Spine on Twitter: https://twitter.com/WenzelSpine
Follow Wenzel Spine on Facebook: https://facebook.com/WenzelSpine
Follow Wenzel Spine on Instagram: https://Instagram.com/wenzelspine

For further information, contact:
Chad Neely, Chief Executive Officer
(512) 469-0600

HORSHAM, Pa., Sept. 25, 2017 /PRNewswire/ — Flower Orthopedics, the leader in Ready-for-Surgery™ extremity implant systems, announces multiple expansions to its product line. “With these latest additions to our portfolio, we continue our commitment to establish the most comprehensive offering of sterile, surgical, efficiency-based products, producing cost savings for our partners,” said Oliver Burckhardt, President and CEO of Flower Orthopedics.

The Flower Efficiency (E-Kit™) Advanced, a multi-functional, sterile, Ready-for-Surgery™ instrument kit contains all the instruments necessary for an implant procedure. The enhanced E-Kits feature instruments designed to reduce surgical steps and facilitate faster surgery. “The new E-Kits expand upon our sterile Ready-for-Surgery™ instrument platform. The E-Kit can be used for Flower’s plating system, as well as, for both our Cannulated headed and Headless Compression Screw systems. It eliminates the hassle of onsite sterilization. A single sterile E-Kit replaces the instruments in two sterilization trays which undergo costly, timely and sometimes ineffective sterilization cycles,” Burckhardt said.

Developed to provide exceptional anatomic fit and to reduce operating room time, FlowerGraft™ is a comprehensive foot reconstruction platform for Evans and Cotton procedures. FlowerGraft™ is the world’s first system containing pre-shaped, bi-cortical allografts packaged in saline, which can be employed with the specifically designed sterile single-use FlowerGraft™ instrument kit. According to Elizabeth Hewitt, DPM in Columbus, OH, “With the grafts packaged in saline and the novel single-use instruments, the FlowerGraft™ System saves me up to 30 minutes of OR time. The low profile plates provide anatomic fixation without affecting the adjacent soft tissues.”

Flower Orthopedics also announces the addition of its Headless Compression Screws to complete its comprehensive Ready-for-Surgery™ cannulated screw platform. The Headless Compression Screws are available across several diameters to accommodate the most common foot, ankle, hand and wrist procedures. Following the principle of driving standardization and surgical efficiency, the Flower Headless Compression screws are used in combination with the Flower E-Kit.

About Flower: Flower Orthopedics was founded in 2012 to drive surgical efficiencies that translate into cost savings. Flower’s development team works tirelessly with leading surgeons focusing on creating advanced implant platforms that are always Ready-for-Surgery^TM.

SOURCE Flower Orthopedics

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

Resurgens Spine Center welcomes three fellowship-trained surgeons to Georgia’s largest spine practice

Safe Orthopaedics Continues to Improve Its Results in the First Half of 2017

Contacts

EOI Announces FDA Clearance for the FLXfit15, the Only 3D Articulated Expandable Cage With 15 degrees of Lordosis Correction

Providence Medical Technology Expands Offering of Posterior Cervical Fusion Solutions

Global Surgeon Experience Demonstrates AxioMed Freedom® Viscoelastic Disc Will Be Revolutionary

Conventus Orthopaedics Appoints Richard Mott to its Board of Directors

Orthobiologics Market Worth 6.06 Billion USD by 2022

Medicrea Financial Calendar Amendment

Contacts

Wenzel Spine Announces Refinements and Extended Size Range of the VariLift®-C

Flower adds to its market leading Ready-For-Surgery™ product line

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS